BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 12951576)

  • 1. Trends in development and approval times for new therapeutics in the United States.
    Reichert JM
    Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
    Reichert JM; Paquette C
    Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can open-source R&D reinvigorate drug research?
    Munos B
    Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling type I error rate for fast track drug development programmes.
    Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
    Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.